GTE 001
Alternative Names: GTE-001Latest Information Update: 29 Jul 2024
At a glance
- Originator GRIT Biotechnology
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Adenocarcinoma
Most Recent Events
- 18 Jul 2024 Phase-I clinical trials in Adenocarcinoma (Late-stage disease, Second line therapy or greater) in China (Parenteral) (NCT06491225)